-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Haemonetics, Raises Price Target to $119

Benzinga·08/21/2026 12:18:46
Listen to the news
Baird analyst David Rescott maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $96 to $119.